论文部分内容阅读
目的:初步估算首钢3个下属企业糖尿病经济负担,以推动糖尿病成本测算工作的进一步开展。方法:以三厂在1992年首都钢铁集团公司糖尿病普查所发现的95例糖尿病患者和77例糖耐量低减(IGT)患者为2个病例组:根据整群随机抽样法,选择三厂1878例非糖尿病、非IGT人群为本次研究的对照组。结果:糖尿病、IGT经济负担分别是对照组的2.69倍和1.25倍。糖尿病、IGT、对照组直接费用与间接费用之比分别为9.34、4.64、9.38。两病例组年人均总费用不存在性别差异,但均随着年龄增加而上升。结论:糖尿病和IGT患者的经济负担高于一般人群,其中绝大部分是直接费用。
OBJECTIVE: To estimate the economic burden of diabetes in Shougang’s 3 affiliated companies for the first time to further promote the cost estimation of diabetes. Methods: The 95 patients with diabetes and 77 patients with impaired glucose tolerance (IGT) discovered by the Three Plants in the Capital Iron and Steel Group Company in 1992 were divided into two groups according to the randomized sampling method: 1878 The non-diabetic, non-IGT population was the control group for this study. Results: The economic burden of diabetes and IGT were 2.69 times and 1.25 times that of the control group respectively. Diabetes, IGT, control group direct costs and indirect costs were 9.34,4.64,9.38. There was no gender difference in the total annual per capita costs for both cases, but both increased with advancing age. Conclusion: The financial burden of diabetes and IGT patients is higher than that of the general population, most of which are direct costs.